Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrimeprazine + perphenazine
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular, Intravenous, Subcutaneous
01
Overview
Methotrimeprazine + perphenazine is a combination of two phenothiazine antipsychotics. Methotrimeprazine, also known as Nozinan or Levoprome, is used in the management of psychosis (particularly schizophrenia) and manic phases of bipolar disorder. It acts primarily by antagonizing dopamine receptors in the brain and also binds to 5HT2 (serotonin) receptors, contributing to its antipsychotic effects[3][8]. Perphenazine, known under brand names such as Trilafon, is used for treating schizophrenia and for controlling severe nausea and vomiting in adults. Its mechanism involves antagonism at dopamine D1 and D2 receptors—reducing abnormal excitement in the brain—and it also blocks alpha adrenergic receptors[1][4][5]. Both drugs are classified as first-generation (typical) antipsychotics.
- Brand names
- NozinanLevopromeTrilafon
- Other names
- methotrimeprazineperphenazine
02
Targets
DRD1 (Dopamine D1 Receptor)ADRA2C (α2C)DRD3 (Dopamine receptor D3)ADRA1A (α1A)ADRA2A (α2A)ADRA2B (α2B)HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)DRD4 (Dopamine D4 Receptor)
Beyond the preview
Go deeper on methotrimeprazine + perphenazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrimeprazine + perphenazine.